Skip to main content

Advertisement

ADVERTISEMENT

poster

Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.
10/26/2023
This qualitative research study assessed the patient experience of anhedonia and its impacts among patients with MDD. Semi-structured concept elicitation interviews were conducted with 1...
10/26/2023
Psychedelic therapy was offered to a couple 'cognitively stuck' on their dyadic journey through their grief work. On, their second mutual ketamine-experience they both entered the transp...
10/26/2023
We present a study on the interplay between genetic variants and gene expression levels in depressed patients’ neurons and its association with antidepressant response. Neuronal expressio...
10/26/2023
Despite a relatively low prevalence, schizophrenia is one of the top 15 causes of disability worldwide and among the most expensive mental disorders to treat. Relapse, commonly associated...
10/26/2023
Clinician perspectives on the use of long-acting injectable antipsychotics (LAIs) for the treatment of schizophrenia are central to understanding real-world barriers to LAI use. In this s...
10/26/2023
We aim to investigate the elevated occurrence of Female Orgasmic Disorder (FOD) within our patient population, attributable to male sexual dysfunction (MSD) in their partners. Through a c...
10/26/2023
In adult patients with schizophrenia, switching from RISPERDAL CONSTA® (RC) to RYKINDO® requires administration of the first RYKINDO injection 4-5 weeks after the last RC injection. For p...
10/26/2023
Clinicians are challenged to diagnose, assess, and treat patients with schizophrenia. This CME based survey assessed current practice gaps among US based psychiatrists related to the diag...
10/26/2023
Precision Medicine and Target-Controlled Infusions (TCI) represent a novel methodology to enhance the effectiveness and durability of ketamine infusion therapy for treatment-resistant dep...
10/26/2023

Advertisement